TScan Therapeutics (NASDAQ:TCRX), a clinical-stage biopharmaceutical company developing T cell receptor (TCR)-engineered T cell therapies for the treatment of cancer, on Wednesday reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update focused on progress across its allogeneic TCR-T platform.
The U.S. Food and Drug Administration cleared Investigational New Drug (IND) applications for TSC-102-A01 and TSC-102-A03, two solid tumor-targeted TCR-T candidates from the company's TSC-102 program.
These clearances enable the initiation of Phase 1 clinical trials to evaluate safety, tolerability and preliminary efficacy in patients with select solid tumors expressing specific cancer-associated antigens.
In the ongoing ALLOHA™ Phase 1 trial evaluating TSC-200 series TCR-T candidates in hematologic malignancies, TScan completed enrollment in Cohort C using product manufactured at commercial scale.
The milestone supports the company's transition toward registrational-enabling studies and potential accelerated approval pathways in high-risk myeloid malignancies.